Quizartinib Poised to Expand FLT3 Inhibition Options in AML

Brittany Lovely and Danielle Ternyila
Published: Tuesday, Apr 16, 2019
Jorge E. Cortes, MD

Jorge E. Cortes, MD

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia (AML), part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Figure. Quizartinib in Adult Patients With Relapsed/Refractory AML2

Figure. Quizartinib in Adult Patients With Relapsed/Refractory AML2 “The results of the QuANTUM-R trial showed an improvement in survival. The hazard ratio was 0.76, essentially meaning an approximately 24% reduction in the risk of death during the observation period of the study,” said Jorge E. Cortes, MD, in an interview with OncologyLive®.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x